Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
Alzheimer's & Dementia · 2025-07 · 21 (7)
DOI: 10.1002/alz.70468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.07.2025. Verfasst von David S Knopman und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Cognitive Dysfunction, Amyloid beta-Peptides, Brain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIA NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute on Aging
Zitieren
APA
Knopman, D. S., Weigand, S. D., Wiste, H. J., Graff-Radford, J., Graff-Radford, N. R., Petersen, R. C., Boeve, B. F., Jr, C. R. J., Lowe, V. J., Machulda, M. M., Fields, J. A., Ramanan, V. K., Botha, H., McCarter, S. J., Jones, D. T., Neth, B. J., Day, G. S., Kantarci, K., Algeciras-Schimnich, A., …, & and the Alzheimer's Disease Neuroimaging Initiative (2025). Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance. Alzheimer's & Dementia, 21(7). https://doi.org/10.1002/alz.70468
Vancouver
Knopman DS, Weigand SD, Wiste HJ, Graff-Radford J, Graff-Radford NR, Petersen RC, et al. Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance. Alzheimer's & Dementia. 2025;21(7). doi:10.1002/alz.70468
BibTeX
@article{Knopman2025,
author = {Knopman, David S and Weigand, Stephen D and Wiste, Heather J and Graff-Radford, Jonathan and Graff-Radford, Neill R and Petersen, Ronald C and Boeve, Bradley F and Jr, Clifford R Jack and Lowe, Val J and Machulda, Mary M and Fields, Julie A and Ramanan, Vijay K and Botha, Hugo and McCarter, Stuart J and Jones, David T and Neth, Bryan J and Day, Gregory S and Kantarci, Kejal and Algeciras-Schimnich, Alicia and Bornhorst, Joshua A and Johnson, Derek R and and the Alzheimer's Disease Neuroimaging Initiative, and the Alzheimer's Disease Neuroimaging Initiative},
title = {Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {7},
doi = {10.1002/alz.70468}
}
EUVIMED